Epigenetic Biomarkers Are Applicable for Risk Stratification in Myelodysplastic Syndromes

被引：1
|
作者：
Mies, Anna [1 ]
Bozic, Tanja [2 ]
Kramer, Michael [1 ]
Franzen, Julia [2 ]
Ehninger, Gerhard [1 ]
Bornhauser, Martin [1 ,3 ]
Platzbecker, Uwe [1 ,3 ]
Wagner, Wolfgang [2 ]
机构：
[1] Univ Hosp Carl Gustav Carus Dresden, Dept Internal Med 1, Dresden, Germany
[2] RWTH Aachen Med Sch, Helmholtz Inst Biomed Engn, Stem Cell Biol & Cellular Engn, Aachen, Germany
[3] German Canc Consortium, Heidelberg, Germany
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3194.3194
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3194
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Risk Stratification in Hypomethylating Agent-Treated Patients With Myelodysplastic Syndromes: A Multivariate Model
    Chien, Kelly S.
    Li, Ziyi
    Urrutia, Samuel
    Kanagal-Shamanna, Rashmi
    Abdelhakeem, Ahmed
    Abuasab, Tareq
    Almanza, Emmanuel
    Ricos, Georgina Gener
    Bataller, Alex
    Bazinet, Alexandre
    Montalban-Bravo, Guillermo
    Short, Nicholas
    Kadia, Tapan M.
    Ravandi, Farhad
    Borthakur, Gautam
    Hammond, Danielle E.
    Swaminathan, Mahesh
    Sasaki, Koji
    Dong, Xiao Qin
    Pierce, Sherry A.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S398 - S398
  • [42] Genetic and epigenetic biomarkers in cancer: Improving diagnosis, risk assessment, and disease stratification
    Verma M.
    Seminara D.
    Arena F.J.
    John C.
    Iwamoto K.
    Hartmuller V.
    Molecular Diagnosis & Therapy, 2006, 10 (1) : 1 - 15
  • [43] Genetic and epigenetic biomarkers in cancer - Improving diagnosis, risk assessment, and disease stratification
    Verma, Mukesh
    Seminara, Daniela
    Arena, Fernando J.
    John, Christy
    Iwamoto, Kumiko
    Hartmullerl, Virginia
    MOLECULAR DIAGNOSIS & THERAPY, 2006, 10 (01) : 1 - 15
  • [44] Practical Recommendations for Reporting and Prognostic Stratification of Myelodysplastic Syndromes
    Emery, Michael J.
    Sagatys, Elizabeth
    Tao, Jiangchuan
    Komrokji, Rami
    Openshaw, Thomas H.
    Movalia, Mayur
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2013, 140 : 215 - 215
  • [45] The value of novel serum biomarkers in risk stratification of the patients with acute coronary syndromes
    Celik, Turgay
    Celik, Murat
    Yuksel, U. Cagdas
    Bugan, Baris
    Iyisoy, Atila
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 146 (02) : 228 - 229
  • [46] RISK FACTORS IN MYELODYSPLASTIC SYNDROMES
    Villa, M. R.
    Gagliardi, A.
    Cuccurullo, R.
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2014, 99 : 615 - 615
  • [47] Prognostic Biomarkers in Acute Coronary Syndromes: Risk Stratification Beyond Cardiac Troponins
    Eggers, K. M.
    Lindahl, B.
    CURRENT CARDIOLOGY REPORTS, 2017, 19 (04)
  • [48] Lower risk myelodysplastic syndromes
    Angelucci, E.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 44 - 44
  • [49] Prognostic Biomarkers in Acute Coronary Syndromes: Risk Stratification Beyond Cardiac Troponins
    K. M. Eggers
    B. Lindahl
    Current Cardiology Reports, 2017, 19
  • [50] Optimizing epigenetic therapy for myelodysplastic syndromes: issues and strategies
    Luebbert, Michael
    LEUKEMIA RESEARCH, 2009, 33 : S1 - S1
12345